ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Defensive Bets Build Ahead of Big Prints

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Options traders turned sharply defensive on EHC this week. Short interest climbed 20.4% in seven days to 3.3% of free float, the highest level since late September. Put activity spiked ahead of the healthcare firm's earnings, with the nearest active expiry sitting on 20 November.

INTC drew its third analyst downgrade in a week. Seaport Global cut the chipmaker to Neutral today, citing PC weakness and foundry execution risks. Intel has active weekly expiries running all the way through January, giving put buyers plenty of runway. Short interest stands at 3.15% of free float, with cost to borrow a near-zero 0.29%, meaning the bet is cheap to hold.

RACE reports on 3 November. Austrian car registration data, which ORTEX alt data shows leads Ferrari revenue by 22 days, is running 75% below the same quarter last year. The fit is classed as weak, but the direction is notable. Options expiries run through December, with same-week contracts expiring today.

MA moves the other way. Keybanc raised its price target to $735 today. The stock carries the highest options score in the S&P 500 screen, with RSI at 69.9 and a next event flagged as a Q3 earnings call. Bulls appear in control of near-term flow.

The broader read: earnings season is splitting the options market cleanly. Healthcare and chip names are attracting defensive hedges. Payments and quality names are drawing call interest.

Stocks in this article

How this article was generated

Generated
30 Oct 2026, 12:50
Prompt version
v1.0
Data sources
Options flowORTEX Alpha signalsAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.